All In Biotech

Free tool

FAERS Monitor: Netspot

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208547 or its brand name (Netspot, Gallium Dotatate Ga-68). Reports on generic versions are filed under their own applications.

Reports

190

Serious

20

11% of reports

Hospitalization

6

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea78
  • scan gallium abnormal29
  • vomiting29
  • abdominal pain20
  • injection site pain20
  • flushing17
  • chest pain11
  • dizziness9
  • erythema8
  • hypersensitivity8
  • urticaria8
  • dyspnoea6
  • feeling abnormal6
  • hyperhidrosis6
  • abdominal discomfort5

Reports by year received

View as table
YearReports
20175
201886
201920
202012
20215
202212
202312
202416
202517
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,969 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
scan gallium abnormalSignal29267791.7138746.82,195,248
flushingSignal1718.511.8266
nauseaSignal7810.99.2719
abdominal painSignal209.56.3146
injection site painSignal207.24.8102
vomitingSignal296.84.9142
chest painSignal116.63.747
urticariaSignal85.32.724
hyperhidrosisSignal65.22.316
hypersensitivitySignal84.82.420
erythemaSignal84.32.217
abdominal discomfortSignal53.31.46
feeling abnormalSignal62.81.35
dizziness92.01.14
dyspnoea61.20.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.